Safety Trial of Monovalent Whole Virus Influenza (H1N1) Vaccine

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01507779
Recruitment Status : Completed
First Posted : January 11, 2012
Last Update Posted : September 23, 2013
Institute of Vaccines and Medical Biologicals, Vietnam
Pasteur Institute, Ho Chi Minh City
Information provided by (Responsible Party):

Brief Summary:
The study hypothesis is that two 0.5 ml doses of non-adjuvanted whole virion monovalent A/H1N1 influenza vaccine (IVACFLU)-—each dose with an HA content of 15 mcg from A/California/07/2009 (H1N1)-like virus-—will be safe and immunogenic in healthy adults.

Condition or disease Intervention/treatment Phase
Influenza Biological: IVACFLU Other: PBS (Phosphate buffered saline) Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Evaluation of The Safety and Immunogenicity of an Influenza A/H1N1 Vaccine (IVACFLU), Produced by IVAC, in Healthy Adults in Vietnam
Study Start Date : April 2012
Actual Primary Completion Date : November 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Influenza vaccine Biological: IVACFLU
IVACFLU is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose
Other Name: whole virion monovalent A/H1N1 influenza vaccine
Placebo Comparator: Placebo Other: PBS (Phosphate buffered saline)
Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.

Primary Outcome Measures :
  1. Safety Profile [ Time Frame: within three weeks after each dose ]
    Immediate reactions occurring within 60 minutes of administration; solicited and unsolicited adverse events occurring through 7 days following any dose; all serious adverse events (SAEs) occurring within 3 weeks of receipt of any dose

  2. Long terms SAEs [ Time Frame: from 3 weeks to 6 months post-dose 2 ]
    Serious adverse events

Secondary Outcome Measures :
  1. Immunogenicity measure 1 [ Time Frame: three weeks after each dose ]
    serum hemagglutination-inhibition antibodies

  2. Immunogenicity measure 2 [ Time Frame: three weeks after each dose ]
    serum neutralizing antibodies using microneutralization assay

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male or female adult 18 (age of legal consent in Vietnam) through 40 years of age at the enrollment visit.
  • Literate and willing to provide written informed consent.
  • Free of obvious health problems, as established by the medical history and screening evaluations, including physical examination.
  • Capable and willing to complete diary cards and willing to return for all follow-up visits
  • For females, willing to utilize reliable birth control measures (intrauterine device, birth control pills, condoms) through the Day 42 visit.

Exclusion Criteria:

  • Participation in another clinical trial involving any therapy within the previous three months or planned enrollment in such a trial during the period of this study.
  • Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to postpone receipt of such vaccines until after the Day 42 visit.
  • Current or recent (within two weeks of enrollment) acute illness with or without fever.
  • Receipt of immune globulin or other blood products within three months prior to study enrollment or planned receipt of such products prior to the Day 42 visit.
  • Chronic administration (defined as more than 14 consecutively-prescribed days) of immunosuppressants or other immune-modulating therapy within six months prior to study enrollment. (For corticosteroids, this means prednisone or equivalent, >=0.5 mg per kg per day; topical steroids are allowed.)
  • History of asthma.
  • Hypersensitivity after previous administration of any vaccine.
  • Other AE following immunization, at least possibly related to previous receipt of any vaccine.
  • Suspected or known hypersensitivity to any of the study vaccine components, including chicken or egg protein.
  • Known hypersensitivities (allergies) to food or the natural environment.
  • Acute or chronic clinically significant pulmonary, cardiovascular, hepatic, metabolic, neurologic, psychiatric or renal functional abnormality, as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives..
  • History of leukemia or any other blood or solid organ cancer.
  • History of thrombocytopenic purpura or known bleeding disorder.
  • History of seizures.
  • Known or suspected immunosuppressed or immunodeficient condition of any kind, including HIV infection.
  • Known chronic HBV or HCV infection.
  • Known active tuberculosis or symptoms of active tuberculosis, regardless of cause.
  • History of chronic alcohol abuse and/or illegal drug use.
  • Pregnancy or lactation. (A negative pregnancy test will be required before administration of study vaccine or placebo for all women of childbearing potential.)
  • History of Guillain-Barre' Syndrome
  • Any condition that, in the opinion of the investigator, would increase the health risk to the subject if he/she participates in the study or would interfere with the evaluation of the study objectives.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01507779

Ben Luc Health Center
Ben Luc, Long An, Vietnam
Sponsors and Collaborators
Institute of Vaccines and Medical Biologicals, Vietnam
Pasteur Institute, Ho Chi Minh City
Study Director: Kathleen M Neuzil, MD, MPH PATH
Study Director: Le V Be, MD, PhD Institute of Vaccines and Medical Biologicals, Vietnam
Principal Investigator: Ho V Thang, MD, MSc Pasteur Institute

Responsible Party: PATH Identifier: NCT01507779     History of Changes
Other Study ID Numbers: IVAC-mH1N1-01
First Posted: January 11, 2012    Key Record Dates
Last Update Posted: September 23, 2013
Last Verified: September 2013

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs